PropThink: Biogen Idec: rFVIIIFc Trials Somewhat Disappointing, but ALS Trials Could be the Next Catalyst

[ACN Newswire] – By Ivan DeryuginThe past few months have been eventful ones for Biogen Idec (NASDAQ:BIIB), as the company awaits the FDA’s decision on BG-12 and continues to build out is pipeline. Last week, Biogen reported … more

View todays social media effects on GILD

View the latest stocks trending across Twitter. Click to view dashboard